Hot Logistics Companies To Watch In Right Now

LONDON -- A month can be a long time when looking at the share price of a particular stock. Here are two companies that have come out of the last 30 days at opposite ends of the profit/loss spectrum:

1. Ocado
The share price of�Ocado� (LSE: OCDO  ) has advanced nearly 54% during the last four weeks or so. The gain is due entirely to news that the firm will now partner with�William Morrison Supermarkets�to help the supermarket move into the online delivery market.

The 25-year agreement will allow Morrisons to license certain technology, logistics, and distribution services in order for the chain to start to build its own online shopping service. In addition, Ocado has agreed to sell to Morrisons half the capacity of its fulfilment center at Dordon.

Ocado has received an up-front payment of 165 million pounds for the deal, most of which will be put back into the research and development of new technology. The payment was a welcome boost to Ocado's balance sheet, and will go some way to reduce the group's financial costs.

Hot Logistics Companies To Watch In Right Now: The Medicines Company(MDCO)

The Medicines Company, a pharmaceutical company, provides various medicines to hospitals for advancing the treatment of critical care patients worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty and for use in patients undergoing percutaneous coronary intervention; and Cleviprex, an intravenous small molecule calcium channel blocker for the reduction of blood pressure, as well as to treat neurocritical care and cardiac surgery patients. Its products under development include Cangrelor that is in Phase III clinical trial acts as an intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation; and Oritavancin, which is in Phase III clinical trial acts as an investigational intravenous antibiotic for the treatment of serious gram-positive bacterial infections, including acute bacterial skin and skin structure infections. The company?s products under development also comprise MDCO-157, a pre-registration stage product for platelet inhibition in patients suffering from acute coronary syndrome (ACS), and patients experiencing myocardial infarction, stroke, or peripheral arterial disease; MDCO-2010, a small molecule serine protease inhibitor that is in Phase II clinical trial used for the reduction of blood loss during surgery; and MDCO-216, which is in Phase I clinical trial used for the reversal of atherosclerotic plaque development and the reduction of the risk of coronary events in patients with ACS. Its products also consist of Argatroban, a direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis; and acute care generic products. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Advisors' Opinion:

• [By Rich Duprey]

  If all goes well in phase 3�trials for�ProFibrix's lead biologic, Fibrocaps -- a treatment�to stop bleeding during surgery -- shareholders of the Netherlands-based drugmaker could receive a hefty payday from The Medicines Company (NASDAQ: MDCO  ) , which says it's willing to buy out the company if it can expect to bring the therapy to market here at home as well as in Europe.

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer The Medicines Company (NASDAQ: MDCO  ) has earned a respected four-star ranking.

• [By Jay Silverman]

  The Medicines Company (MDCO) is delivering on its plan to become the leading acute care provider of medicines in the hospital setting—in acute cardiovascular care, surgical, and perioperative medicine, and hospital-based infectious disease.

Hot Logistics Companies To Watch In Right Now: Capital Product Partners L.P.(CPLP)

Capital Product Partners L.P., a shipping company, provides seaborne transportation of refined oil products and chemicals. It provides marine transportation services under medium- to long-term time charters or bareboat charters. As of July 13, 2011, the company?s fleet consisted of 22 double-hull tankers, including 18 medium range (MR) tankers, 2 small product tankers, 1 Suezmax crude oil tanker, and 1 Capesize bulk carrier. Its tankers are capable of carrying crude and refined oil products, such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals, including ethanol. Capital GP L.L.C. operates as a general partner of the company. Capital Product Partners L.P. was founded in 2007 and is headquartered in Piraeus, Greece.

Top High Tech Stocks To Invest In 2015: Sunedison Inc (SUNE)

SunEdison Inc, formerly MEMC Electronic Materials, Inc., incorporated on October 1, 1984, is engaged in the development, manufacture and sale of silicon wafers. The Company is a developer and seller of photovoltaic energy solutions. Through Solar Materials and Solar Energy (SunEdison), it is a developer of solar energy projects. The Company operates in two segments: semiconductor materials and solar energy. The Company�� Solar Energy segment includes the operations of its old Solar Materials segment, as well as its SunEdison business. In the Semiconductor Materials, the Company offers wafers with a variety of features. The Company�� wafers vary in size, surface features, composition, purity levels, crystal properties and electrical properties.

Semiconductor Materials

The Company�� monocrystalline wafers for use in semiconductor applications range in size from 100 millimeter to 300 millimeter and are round in shape for semiconductor customers because of the nature of their processing equipment. Its wafers are used as the starting material for the manufacture of various types of semiconductor devices, including microprocessor, memory, logic and power devices. In turn, these semiconductor devices are used in computers, cellular phones and other mobile electronic devices, automobiles and other consumer and industrial products. Its monocrystalline wafers for semiconductor applications include four general categories of wafers: prime, epitaxial, test/monitor and silicon-on-insulator (SOI) wafers.

The Company�� prime wafer is a polished, pure wafer with an ultraflat and ultraclean surface. The Company�� epitaxial (epi), wafers consist of a thin silicon layer grown on the polished surface of the wafer. Typically, the epitaxial layer has different electrical properties from the underlying wafer. This provides customers with isolation between circuit elements than a polished wafer. Its AEGIS product is designed for certain specialized applications requiring high resis! tivity epitaxial wafers and its MDZ product feature. The AEGIS wafer includes a thin epitaxial layer grown on a standard starting wafer. The AEGIS wafer�� thin epitaxial layer eliminates harmful defects on the surface of the wafer, thereby allowing device manufacturers to increase yields. The Company supplies test/monitor wafers to its customers for use in testing semiconductor fabrication lines and processes. An SOI wafer is a different starting material for the chip making process.

Solar Energy

The Company�� Solar Energy segment provides solar energy services that integrate the design, installation, financing, monitoring, operations and maintenance portions of the downstream solar market to provide a solar energy service to its customers. As of December 31, 2012, SunEdison interconnected over 675 solar power systems representing 989 megawatt of solar energy generating capacity. As of December 31, 2012, SunEdison had 73 megawatt of projects under construction and 2.6 gigawatts in pipeline. In support of its downstream solar business, its Solar Energy segment manufactures polysilicon, silicon wafers and solar modules. Additionally, its Solar Energy segment will sell solar modules to third parties in the event the opportunity aligns with itsinternal needs. It provides its downstream customers with a way to purchase renewable energy by delivering solar power under long-term power purchase arrangements with customers or feed-in tariff arrangements with government entities and utilities. Its SunEdison business is dependent upon government subsidies, including United States federal incentive tax credits, state-sponsored energy credits and foreign feed-in tariffs. The Company�� solar wafers are used as the starting material for crystalline solar cells.

The Company competes with Shin-Etsu Handotai, SUMCO, Siltronic and LG Siltron, SunPower Corporation, First Solar, Inc., Enerparc, Sharp Corporation (Recurrent Energy), Phoenix Solar, BELECTRIC, JUWI Solar Gmbh, and S! olar City! .

Advisors' Opinion:

• [By Roberto Pedone]

  Another semiconductor player that's starting to move within range of triggering a near-term breakout trade is SunEdison (SUNE), which provides technology solutions to corporations, utilities, governments and chip manufacturers to transform lives around the world. This stock has been red hot so far in 2013, with shares up big by 150%.

  If you look at the chart for SunEdison, you'll notice that this stock recently formed a double bottom chart pattern at $7.08 to $7.13 a share. Following that bottom, shares of SUNE have started to spike higher and move within range of its 50-day moving average at $8.30 a share and close to triggering a near-term breakout trade.

  Traders should now look for long-biased trades in SUNE if it manages to break out above its 50-day at $8.30 a share and then once it takes out more key resistance levels at $8.35 to $8.41 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 5.81 million shares. If that breakout triggers soon, then SUNE will set up to re-fill some of its previous gap down zone from August that started at $10 a share. If this stock gets into that gap with volume, then this stock could easily re-test or take out its 52-week high at $10.47 a share.

  Traders can look to buy SUNE off any weakness to anticipate that breakout and simply use a stop that sits right below those double bottom support levels at $7.13 to $7.08 a share. One can also buy SUNE off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Paul Ausick]

  Another possible target is the solar energy division of SunEdison Inc. (NYSE: SUNE). The company said last week that it would be spinning off its semiconductor business into a separate company next year. In the second quarter of this year the semiconductor segment provided about 60% of SunEdison�� total revenues of $401.3 million. But the company�� solar business has historically provided most of the revenues and could be both a target as operating losses in the solar energy segment continue.

Hot Logistics Companies To Watch In Right Now: Petrodorado Energy Ltd (PDQ.V)

Petrodorado Energy Ltd. engages in the exploration and development of petroleum and natural gas properties in South America. It holds interests in nine blocks, including four lower risk blocks and five highly prospective blocks located in Columbia, Peru, and Paraguay. The company is headquartered in Calgary, Canada with an additional office in Bogota, Colombia.

Hot Logistics Companies To Watch In Right Now: Journal Communications Inc. (JRN)

Journal Communications, Inc. operates as a media company in the United States. Its Broadcasting segment operates approximately 34 radio stations and 15 television stations in 12 states; and 1 television station under marketing agreement. Its television and radio stations provide targeted and relevant local programming to serve listeners, viewers, and advertisers. The company�s Publishing segment publishes Milwaukee Journal Sentinel, which serves as the daily newspaper for the Milwaukee metropolitan area; and various community newspapers and shoppers in Wisconsin. Its Milwaukee Journal Sentinel newspaper is distributed through independent contract carriers and agents. The company also operates various Websites, including JSOnline.com and Milwaukeemoms.com, and the MyCommunityNOW family of 26 community Websites that provide editorial and advertising content. In addition, it publishes niche publications for advertisers and readers in the agricultural market; and offers comme rcial printing services, including cold-Web printing, sheet-fed printing, electronic prepress, mailing, bindery, and inserting for other weekly and monthly publications. Journal Communications, Inc. was founded in 1882 and is headquartered in Milwaukee, Wisconsin.

Hot Logistics Companies To Watch In Right Now: Clovis Oncology Inc (CLVS.O)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hE NT1 levels.

CO-1686-an Oral EGFR Mutant-Select! i! ve Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line t reatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the o ral formulation, to determine an appropriate dose and s! chedu! le! .

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Hot Logistics Companies To Watch In Right Now: Newport Corporation(NEWP)

Newport Corporation and its subsidiaries provide technology products and systems to scientific research, microelectronics, aerospace and defense/security, life and health sciences, and industrial markets in the United States, Europe, and the Pacific Rim. The company operates in three divisions: Photonics and Precision Technologies (PPT), Lasers, and Ophir. The PPT division provides photonics instruments and systems; vibration isolation systems and subsystems; precision positioning devices, systems, and subsystems; optics and optical hardware; opto-mechanical subassemblies and subsystems; and advanced manufacturing systems. It also offers automated systems for various applications in the manufacture of solar panels, and communications and electronic devices, including microwave, optical, radio frequency, and multi-chip modules. The Lasers division provides laser and laser-based system, such as ultrafast lasers and systems, diode-pumped solid state Q-switched lasers, diode-p umped solid state continuous wave (CW) and quasi-CW lasers, pulsed Nd:YAG and tunable lasers, and gas lasers. The Ophir division offers optics, photonics instruments, and three-dimensional non-contact measurement equipment and sensors. It also provides laser instrumentation, including laser power and energy meters, and laser beam profilers. This division serves the scientific research, microelectronics, aerospace, defense/security, life and health sciences, and industrial markets. The company offers its products under the ILX Lightwave, New Focus, Newport, Ophir, Optimet, Oriel Instruments, Richardson Gratings, Spiricon, and Spectra-Physics names. It sells its products to original equipment manufacturers and end-user customers through direct sales organizations, a network of independent distributors, and sales representatives, as well as through product catalogs and Web sites. Newport Corporation was founded in 1938 and is headquartered in Irvine, California.

Advisors' Opinion:

• [By Evan Niu, CFA]

  What: Shares of Newport (NASDAQ: NEWP  ) got crushed today, down by as much as 12% after the company reported earnings that fell short of expectations.

Hot Logistics Companies To Watch In Right Now: ASA Gold and Precious Metals Limited (ASA)

ASA Gold and Precious Metals Limited is a self management investment trust. The firm invests in the public equity markets across the globe. It primarily invests in stocks of companies engaged in the exploration, mining or processing of gold, silver, platinum, diamonds, or other precious minerals. ASA Gold and Precious Metals Limited was founded in 1958 and is based in San Mateo, California.

Advisors' Opinion:

• [By Joe Eqcome]

  Actionable Items:

  Highest Positive Spread: Nuveen Mortgage Opportunity Term Fund (JLS)Focus Stock: LMP Real Estate Income Fund (RIT)Last Week's Focus Stock: ASA Gold and Precious Metals (ASA)

  ECB cuts its rates: The European Central Bank (ECB) will cut its benchmark rate a quarter-of-a-point to 0.5%.

Hot Logistics Companies To Watch In Right Now: Melkior Resources Inc(MKR.V)

Melkior Resources Inc., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral resource properties in Ontario and Quebec, Canada. It explores for gold, uranium, nickel, copper, molybdenum, zinc, and platinum group metals. The company primarily focuses on its 100% owned Carscallen Timmins West property, which consists of 104 claim units covering 16.64 square kilometers located to the southwest of the city of Timmins. Melkior Resources Inc. is headquartered in Montreal, Canada.